LY6E (F8Y1R) Rabbit Monoclonal Antibody recognizes endogenous levels of total LY6E protein.

Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the amino terminus of human LY6E protein. This antibody recognizes residues surrounding Val49 of human LY6E protein.

The Ly-6 complex is a series of genes found on chromosome 15. These genes code for several different proteins that can be used as surface markers. The family members vary in their biological expression and have been shown to be involved in cell signaling and cell adhesion (1). The structure of these proteins includes a motif known as the LU domain, which contains three loops composed of disulfide bonds. These bonds are formed by 8 to 10 cysteines that can cause differences in the length of the loops as well as the sequences at each tip (2,4). There are 11 known Ly-6 genes on murine chromosome 15 that code for different proteins. These family members, excluding secreted Ly6/Plaur domain-containing 1 (LYPD1), encoded by the Slurp1 gene, are attached to the cell surface via a GPI anchor near the C-terminus. The structure of these proteins may play a role in transmembrane interactions and downstream signaling cascades (1,2). Ly-6 proteins have been widely used as differentiation markers on hematopoietic cells. The ability to isolate and express specific Ly-6 antibodies through hybridoma technology has allowed researchers to identify unique proteins (1). These proteins are expressed on subsets of immune cells at different stages of development, such as T cells, B cells, monocytes, granulocytes, and macrophages (1-6).

Lymphocyte antigen 6 family member E (LY6E), also known as stem cell antigen-2 (SCA-2), thymic shared antigen-1 (TSA-1), or retinoic acid-induced gene E (RIG-E), is widely expressed across various tissues, including the liver, spleen, lungs, and brain, as well as on several immune cell subsets. It plays critical roles in immune regulation, viral infection, and cancer progression, and is heavily induced by type I interferon (IFN). LY6E acts as a restriction factor against human coronaviruses by interfering with spike protein-mediated membrane fusion and blocking viral entry into host cells. Conversely, LY6E promotes the infection of other viruses, such as HIV-1, dengue, and Zika, by enhancing viral entry and fusion (7,8). LY6E is frequently overexpressed in several human malignancies, including breast and gastric cancers, where high expression correlates with poor survival outcomes (9). Recent research indicates that LY6E promotes tumor immune escape by facilitating the accumulation of M2 macrophages, driving the exclusion of CD8⁺ cytotoxic T cells from the tumor microenvironment (10). LY6E plays a complex role in regulating T cell activation and B cell development. It is heavily induced by IFN, acting as a classic interferon-stimulated gene (ISG). LY6E modulates T-lymphocyte proliferation and activation by interacting with CD3Z/CD247 (the zeta chain of the T-cell receptor complex) and can influence TCR sensitivity (10). The high expression of LY6E in tumors has established it as a promising target for pharmaceutical intervention, including antibody-drug conjugates (ADCs) (11). In the context of autoimmune disease, elevated LY6E levels are associated with systemic lupus erythematosus (SLE) activity and correlate with increased disease severity, likely due to the chronic interferon signature present in SLE patients (12).